Clinical trial: Low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 5, 2009, Pages 444-451

  Angelico, F ^a   Francioso, S ^b   Del Ben, M ^a   Feole, K ^a   Carbone, M ^b   Pignatelli, P ^a   Violi, F ^a   Angelico, M ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPEGINTERFERON ALPHA2A; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHOLESTEROL, LDL; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68249096833     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04055.x     Document Type: Article

References (42)

1. Fried MW, Shiffman ML, Rajender Reddy K, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
2. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2008 16 : 75 90.
3. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004 53 : 15 8.
4. Akuta N, Suzuki F, Kawamura Y, et al. Predictors of viral kinetics to Peginterferon plus Ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007 79 : 1686 95.
5. Yu JW, Wang GQ, Sun LJ, LI SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007 22 : 832 6.
6. Poordad F, Reddy R, Martin P. Rapid virological response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008 46 : 78 84.
7. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)-ribavirin therapy. Hepatology 2006 43 : 954 60.
8. Dalgard O, Mangia A. Short-term therapy for patientswith hepatitis C virus genotype 2 or 3 infection. Drugs 2006 66 : 1807 15.
9. Backus LI, Boothyroyd DB, Phillips R, Mole LA. Predictors of response of US veterans to treatment for hepatitis C virus. Hepatology 2007 46 : 37 47.
10. Kaua A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008 49 : 634 51.
11. Salmeron J, Casado J, Rueda PM, et al. Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin. J Clin Virol 2008 41 : 264 9.
12. Economou M, Milionis H, Filis S, et al. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 2007 23 : 586 91.
13. Gopal K, Johnson TC, Gopal S, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006 44 : 335 40.
14. Henning BJ, Hellier S, Frodsham AJ, et al. Association of low-density lipoprotein receptor polymorphism and outcome of hepatitis C infection. Genes Immun 2002 3 : 359 67.
15. Zografos TA, Liaskos C, Rigopoulou EI, et al. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol 2008 103 : 605 14.
16. Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat 2008 15 : 129 36.
17. Hanouneh IA, Feldstein AE, Lopez R, et al. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2008 6 : 584 9.
18. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008 48 : 28 34.
19. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972 18 : 499 502.
21. Matthews DR, Hosker JP, Rudenski AS, Nailor BA, Treacher BF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985 28 : 412 9.
22. Lau JY, Davis GL, Prescott LE, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med 1996 124 : 868 76.
23. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358 : 958 65.
24. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007 46 : 403 10.
25. Fernandez-Rodriguez CM, Lopez-Serrano P, Alonso S, et al. Long-term reversal of hypocholesterolemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Alim Pharmac Ther 2006 24 : 507 12.
26. Molina S, Castet V, Fournier-Wirth C, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007 46 : 411 9.
27. Bader T, Fazili J, Madhoun M, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008 103 : 1383 9.
28. Torres DM, Harrison SA. HCV replication and statin pleiotropism: an adjuvant treatment panacea? Am J Gastroenterol 2008 103 : 1390 2.
29. O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007 45 : 895 8.
30. Montuschi P, Barnes P, Roberts LJ. Insights into oxidative stress: the isoprostanes. Curr Med Chem 2007 14 : 703 17.
31. Ferro D, Basili S, Praticò D, et al. Vitamin E reduces monocyte tissue factor expression in cirrhotic patients. Blood 1999 93 : 2945 50.
32. Sk J, Pemberton PW, Smith A, et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol 2002 36 : 805 11.
33. Konishi M, Iwasa M, Araki J, et al. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J Gastroenterol Hepatol 2006 21 : 1821 5.
34. Levent G, Ali A, Ahmet A, et al. Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy. J Transl Med 2006 4 : 25 31.
35. von Herbay A, Stahl W, Niederau C, Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free Radic Res 1997 27 : 599 605.
36. Melhem A, Stern M, Shibolet O, et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol 2005 39 : 737 42.
37. Tarantino G, Conca P, Sorrentino P, Ariello M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 2006 21 : 1266 8.
38. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005 100 : 1509 15.
39. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to Peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005 128 : 636 41.
40. Chu CJ, Lee SD, Hung TH, et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2009 29 : 46 54.
41. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008 47 : 2127 33.
42. Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: a distinct syndrome? Intern Emerg Med 2008 3 : 99 108.